key: cord-0789453-bacvcxvs
authors: Yadava, Om Prakash
title: Post-COVID elective surgery—‘to be or not to be’
date: 2021-04-19
journal: Indian J Thorac Cardiovasc Surg
DOI: 10.1007/s12055-021-01199-w
sha: 69a8d1956a67337628307fa633f72f62347f24ac
doc_id: 789453
cord_uid: bacvcxvs

nan

we are intuitively postponing surgeries until the tachycardia settles, both baseline and exertional oxygen saturations normalise and there is radiological clearance of lung shadows on computerised tomography (CT) scan of the chest. However, there is no objectivity to decision making, and surgery is being timed either empirically or based on low-level evidence from small observational studies.

A recent prospective, multicentre cohort study, carried out by the University of Birmingham in England, attempts to bring some granularity to this conundrum of the timing of elective surgery following a COVID infection [1] . In this study of 140,231 patients undergoing surgeries in October 2020 at various participating hospitals in 116 countries in the COVIDSurg Collaborative, 2.2% (n, 3127) had a preoperative Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) diagnosis established. Authors used logistic regression models to calculate adjusted 30-day mortality rates stratified according to the time-gap between the first diagnosis of infection to the actual performance of the surgery and found that 30-day mortality was a whopping 9.1% for patients whose surgeries were performed within 2 weeks of diagnosis of COVID. This mortality reduced sequentially, as surgery was taken remote from the diagnosis of COVID (6.9% for surgery performed between 3 and 4 weeks; 5.5% for surgery between 5 and 6 weeks and 2% for surgery performed seven or more weeks after the diagnosis of COVID.) In fact, at this time frame of 7 weeks, there was no statistically significant difference in 30-day mortality from patients without SARS-CoV-2 infection (1.5%). The study further found that if the patient remained symptomatic with COVID-19-related symptoms, then the elevated surgical risk continued even beyond 7 weeks (6% mortality), as compared to those where the symptoms had resolved (mortality 2.4%) or who had been asymptomatic (mortality 1.3%).

It would therefore logically behove us to postpone surgery in stable patients to at least 7 weeks after the diagnosis of COVID in asymptomatic patients and even longer for those with ongoing symptoms of long COVID. In a press release, the authors issue a caveat, 'decisions regarding delaying surgery should be tailored for each patient, since the possible * Om Prakash Yadava op_yadava@yahoo.com advantages of delaying surgery for at least 7 weeks following SARS-CoV-2 diagnosis must be balanced against the potential risks of delay', thereby suggesting that the decisions have to be personalised and customised to the acuity of the disease process, for which surgery is being contemplated. Even though this paper does not address the speciality of CTVS specifically, the lessons can be extrapolated and are equally relevant to us. We may be served well by the dictum: when in doubt, just hold your horses!

Informed consent Not required.

The author declares no competing interests.

Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

National Heart Institute, New Delhi, India